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Microsoft Excel. The model compares the cost-effectiveness of
standard diagnostics with the one of ILR-enhanced diagnostic
pathways. Number of positive diagnoses was used as the
outcome measure. The number of diagnostic tests per patient and
the yield of each test were found in published clinical literature.
Cost data were taken from Dutch national sources. Sensitivity
analyses were conducted using Monte Carlo Simulation.
RESULTS: Literature and sensitivity analyses clearly show that
the ILR-based pathway has a signiﬁcantly higher capacity of
providing a correct diagnosis (33.7% vs. 4.1%) within the same
timeframe. The cost per diagnosis in the ILR-based pathway was
slightly higher than the cost per diagnosis of more conventional
care (approximately €1200 more needed per diagnosis with
ILRs). CONCLUSIONS: ILRs can be considered an established,
safe and efﬁcient addition to syncope diagnostics. They provide
physicians with excellent diagnostic yield, enabling timely and
correct treatment of patients whose condition could remain undi-
agnosed. Cost per diagnosis demonstrates the cost-effectiveness
of their use. Potentially, ILRs can also reduce time-to-diagnosis
and operational expenditure of the hospital. Should that be the
case, ILRs can be even more cost-effective while enabling more
patients to get life-saving treatment faster.
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OBJECTIVES: The IDEAL trial (Incremental Decrease in End
Points through Aggressive Lipid Lowering) was an open label,
blinded endpoint evaluation of 8888 patients with history of
acute myocardial infarction (MI) who were randomized to ator-
vastatin 80 mg or simvastatin 20–40 mg. The median follow-up
was 4.8 years. Major coronary events (coronary death, hospital-
ization for MI, or resuscitated cardiac arrest) were reduced by
11%, (hazard ratio [HR], 0.89; 95% conﬁdence interval [CI],
0.78, 1.01; P = 0.07). There was a 16% relative risk reduction in
all cardiovascular events (HR 0.84, 95% CI: 0.76 to 0.91). The
objective of the study was to asses the cost-effectiveness ratio of
atorvastatin 80 mg versus simvastatin 20–40 mg among patients
with history of coronary heart disease (CHD) in Spain taking
into account all CV events. METHODS: A within trial pharma-
coeconomic analysis was developed to estimate cost per event
avoided. Direct (hospitalization, drugs) and indirect costs (lost
production due to work absence) were included in the model. To
estimate the cost of these hospitalizations, drug reimbursement
group (DRG) was used. Effectiveness was estimated as the
number of events in both arms. RESULTS: After 4.8 years,
treatment with intensive atorvastatin could avoid 1 in 6 CV
events compared with moderate simvastatin therapy among
patients with CHD. Despite atorvastatin having a higher drug
cost, this was offset by lower cost of reduced hospitalizations and
work days lost for patients receiving atorvastatin treatment.
Using Spanish costs the incremental cost for atorvastatin to avoid
an event was €15,168. CONCLUSIONS: In a cohort of 8888
Spanish patients with CHD one cardiovascular event could be
prevented for cost of €1520 euros/patient over 4.8 years. Based
on these results, it appears that even in a low cost generic market,
high dose atorvastatin is a good option compared to standard
therapy with simvastatin.
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OBJECTIVES: The timely diagnosis of deep venous thrombosis
(DVT) is critical because this disorder can be life threatening.
However, referring all patients suspected of DVT for ultrasound
(US) testing is inefﬁcient since 80 to 90%of those referred have no
DVT. Therefore, we investigated the cost-effectiveness of a diag-
nostic strategy based on a point of care d-dimer test combined
with a clinical decision rule that was documented to be safe in
primary care (AMUSE study). METHODS: A model based cost-
effectiveness analysis was conducted in conjunction with a recent
multi centre prospective diagnostic study (AMUSE, N = 1002). A
Markov model with a ﬁve year time horizon was used to compare
the AMUSE strategy to two hospital based strategies: ultrasound
for all and a hospital decision rule. Probabilities were derived from
AMUSE and the literature. Societal costs and health state utilities
were used. One way and probabilistic sensitivity analyses were
conducted. Cost-effectiveness acceptability curves were con-
structed. RESULTS: The AMUSE strategy has both slightly lower
costs and less quality adjusted life years (QALYs) than both
hospital based strategies. The ultrasound for all strategy has the
highest costs andQALYs, but is not cost-effective as compared the
hospital decision rule strategy. The AMUSE strategy compared to
the hospital decision rule strategy resulted in a mean saving
of €138, and a mean QALY loss of 0.002. The incremental
cost-effectiveness ratio is €56,436 per QALY lost. The cost-
effectiveness acceptability curves show that the AMUSE strategy
has the highest probability of being cost-effective, even exceeding
ceiling ratios of €80,000 per QALY. CONCLUSIONS: The
AMUSE strategy to exclude DVT in primary care is not only safe,
but also has the highest probability of being cost-effective as
compared to hospital based strategies to diagnose DVT.
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OBJECTIVES: Hypertension and dyslipidemia are highly preva-
lent, often concurrent and act independently, as well as together,
to increase the risk of cardiovascular disease (CVD). This study
sought to investigate the cost-effectiveness of a single-pill com-
bination of amlodipine/atorvastatin (SPAA) for the primary pre-
vention of CVD (comprising coronary heart disease and ischemic
stroke) in Korea. METHODS: A Markov model was developed
with four health states: ‘Alive without CVD’, ‘Alive with CVD’,
‘Dead from CVD’ and ‘Dead from non-CVD causes’, The model
cohort used comprised 171 Korean adults aged 55 years from
the 2005 Korea National Health and Nutritional Examination
Survey (KNHANES) who were CVD-free but met current
Korean criteria for treatment with SPAA. Follow-up was simu-
lated for 40 years. Cardiovascular risk was estimated for each
subject individually using a published, multivariable, Asian-
speciﬁc equation. With subsequent cycles, the cardiovascular
risk proﬁle of each subject was updated. Data regarding the
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dose-speciﬁc efﬁcacy of SPAA at reducing systolic blood pressure
and total cholesterol were drawn from published clinical trial
data (RESPOND), while costs were sourced from Korean phar-
maceutical pricing lists. SPAA comprised weighted average doses
of the ﬁxed-dose combinations of amlodipine 5 mg / atorvastatin
10 mg and 5 mg/20 mg, based on market distribution in Korea.
A 20% price reduction after one year was implemented to reﬂect
patent expiry. Costs of CVD were derived from 2008 Korean
Health Insurance Review and Assessment Service (HIRA) esti-
mates. Utility values for CVD were obtained from published
literature based on 2005 KNHANES data. RESULTS: Compared
to placebo (no treatment), the incremental cost-effectiveness
ratios associated with SPAA were 1,428,681 Korean won (KW)/
QALY and 1,989,858 KW/YoLS. (One thousand KW equates to
approximately one US dollar.) Sensitivity analyses indicated these
results to be robust. CONCLUSIONS: SPAA represents a cost-
effective strategy for the primary prevention of CVD in Korea.
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OBJECTIVES: Chronic heart failure (CHF) is associated with a
substantial clinical and economic burden that impacts signiﬁ-
cantly on health care systems. The objective of this study is to
assess the cost-utility of a new home telemonitoring (HTM)
project in elderly CHF outpatients. METHODS: This prospec-
tive, 6-month, randomised trial was designed to compare the
cost-effectiveness of a HTM project versus usual care (UC) in
elderly patients with CHF, receiving optimal treatment and coun-
selling. A total of 24 patients (aged 66–92 years) were assigned
randomly to HTM or UC. At baseline and at the end of the study,
all patients had a complete cardiologist’s assessment, including
quality of life. The evaluation of the cost of HTM includes the
cost of drug therapy, monitoring, treating side-effects, hospital-
izations and devices. All costs were calculated from a third-party
payer perspective, in 2007 Euros. RESULTS: The mean duration
of the follow-up was similar for the two groups (136.92  36.65
days, P > 0.05). There was a non-statistically signiﬁcant reduc-
tion in hospital readmissions, hospitalisation days, physicians’
visits, laboratory tests and total costs (P > 0.05) for HTM group.
However, HTM was associated with a signiﬁcant improvement
in the QoL measured with the generic health-related EQ-5D
questionnaire (10.00  7.24, P < 0.001) and a small incremental
gain of 0.13  0.24 quality-adjusted-life-years (QALYs) over
UC. The analysis showed that the average incremental cost of
HTM was €12,909  €53,313/QALY gained. CONCLUSIONS:
HTM is likely to be a cost-effective intervention compared with
UC in elderly CHF outpatients in Greece. However, further
studies with more patients and longer duration are needed to
conﬁrm these results.
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OBJECTIVES: To investigate the potential beneﬁt of adding
genetic testing to a pharmacist-managed anticoagulation service
for hospitalized patients on warfarin. METHODS: Using deci-
sion analytic modeling we constructed a decision tree model. The
decisions used were a treat-all and a treat-none approach. The
outcome of interest was minimizing the number of adverse events
(bleeding or thrombitic event). Model parameters were primarily
based on institutional data. Additional information from the
literature or expert opinion was used if needed. One-way sensi-
tivity analyses were performed on unknown parameters to deter-
mine decision thresholds. Two parameters, percentage of patients
beneﬁting from testing and rate of reduction of adverse event
rates due to genetic test results, were given special attention as no
prior information is available. Probabilistic sensitivity analysis
was also conducted. A willingness-to-pay of $35,000 per avoided
adverse event was used as the decision threshold. RESULTS:
Sensitivity analysis showed the decision choice to be affected by
the values of both parameters of interest (20% prevalence and
8% reduction respectively). Baseline analysis resulted in the
treat-all approach to cost an additional $102 per patient on
average and avoid 8 adverse events per 10,000 patients. Proba-
bilistic analysis determined the point at which each decision was
equally likely to be optimal was at a willingness-to-pay of
$140,000. Holding the reduction rate constant the rate of
patients beneﬁtting from the test would need to be as high as
40% before the treat-all approach becomes optimal. Similarly,
the reduction rate would need to be as high as 16% for the
treat-all approach to be optimal. CONCLUSIONS: The percent-
age of patients that would beneﬁt from testing, as well as the
reduction in adverse event rates due to testing, inﬂuence the
decision of treatment approach. The addition of testing all
patients could potentially be cost-effective with sufﬁciently high
enough prevalence and adverse event reduction rates.
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OBJECTIVES: Contrast-induced adverse drug reactions (ADRs),
including contrast-induced nephropathy, are common among
high-risk patients undergoing angiography (e.g., patients with
diabetes mellitus and renal impairment). These ADRs cause
extended hospital stays and additional medication use, leading to
increased cost. We examine the cost-effectiveness of the use of 2
contrast media, in patients at high risk of contrast-induced ADRs,
from the perspective of 5 European countries (Germany, Italy,
Spain, Sweden, and UK). METHODS: A multi-country decision-
analytic model was constructed to estimate the cost-effectiveness
of an isosmolar contrast agent (iodixanol) compared to a low-
osmolar contrast medium (iohexol). The emphasis of the model
was to consider differences in the incidence of severe ADRs in
patients at high risk of contrast-induced nephropathy. The analy-
sis was based on a European randomised controlled trial
(NEPHRIC), in which patients receiving angiography with iodix-
anol had statistically fewer severe ADRs than those with iohexol.
Patients in the study were 18 years of age or older, referred for
coronary or aortofemoral angiography, and had diabetes with
stable serum creatinine concentrations (men: 1.5 to 3.5 mg/dL;
women: 1.3 to 3.5 mg/dL). ADRs considered included acute renal
failure, arrhythmia, cardiovascular events, pulmonary edema, and
multiple-organ failure. Resource use, including hospital days,
medical visits, contrastmedium,medications, laboratory tests and
hospital procedures, were obtained from the NEPHRIC clinical
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